The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial.
Lowell Anthony
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Marc Peeters
No relevant relationships to disclose
John Hainsworth
No relevant relationships to disclose
Eric Baudin
Consultant or Advisory Role - Novartis
Dieter Hoersch
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Covidien; Eckert and Ziegler ; Eckert and Ziegler ; Ipsen; ITG; Novartis; Pfizer
Judith Klimovsky
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Karen Grouss
Employment or Leadership Position - Novartis
Valentine Jehl
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marianne Pavel
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Novartis
James Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Novartis